Brief: Allena Pharmaceuticals Completes Animal Proof-Of-Concept Study For ALLN-346
19/06/2018 13:11
June 19 (Reuters) - Allena Pharmaceuticals Inc ALNA.O :
* ALLENA PHARMACEUTICALS COMPLETES ANIMAL PROOF-OF-CONCEPT
STUDY
FOR ALLN-346, LEAD PRODUCT CANDIDATE FOR HYPERURICEMIA IN THE
SETTING OF ADVANCED CHRONIC KIDNEY DISEASE
* ALLENA PHARMACEUTICALS INC - EXPECTS TO FILE AN IND WITH
U.S.
FOOD AND DRUG ADMINISTRATION IN FIRST HALF OF 2019
Source text for Eikon: ID:nGNX6c3Psy
Further company coverage: ALNA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allena Pharmaceuticals
See all newsBrief: Allena Pharmaceuticals Inc - On September 6, Received Notice From Nasdaq That Its Shares Will Be Suspended At Open Of Business On September 8, 2022
U.S. STOCKS ON THE MOVE-Relmada, Entera Bio, Eli Lilly
U.S. STOCKS ON THE MOVE-ChannelAdvisor, HyreCar, ADT, miners
U.S. STOCKS ON THE MOVE-Timken, Bed Bath & Beyond, HyreCar, chip stocks
Allena down on bankruptcy filing